Clinical Trial Update: Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC [Phase 2]

View source ↗

Summary

This Phase 2 trial of durvalumab plus tremelimumab as adjuvant therapy for resected non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Columbia University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN